The combination treatments revealed synergistic delta scores between the CX3CR1 inhibitor KAND567 [17], from here on referred to as CX3CR1i, and the DNA-damaging platinum drugs carboplatin and cisplatin in all cancer cell lines tested, including the isogenic cancer cell lines sensitive (PEO1, A2780) and resistant (PEO1.C2-4, A2780Cis) to platinum drugs (Figure 1A and Figure S1). The gene discussed is CX3CR1; the disease is cancer.